{"publication_id":"3591803f-c88e-47e8-a088-a212f55ad36d","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors","doi":"10.3390/ijms23073651","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","doi":"10.1177/2047487318755531","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}]}